- Home
- MXCT
MXCT
MaxCyte Inc.
as of 08-21-2026 3:45pm EST
MaxCyte Inc is a life sciences company focused on advancing the discovery, development, and commercialization of next-generation cell therapies. It uses its proprietary cell engineering technology platform to support biotechnology and pharmaceutical customers in cell therapy, gene editing, immuno-oncology, and biologic development. It operates in one segment: cell engineering technology, which generates revenue mainly from product sales, licenses, research and clinical license fees, and program-related revenues as its SPL customers achieve development and regulatory milestones. Its platform, the ExPERT Platform, is based on Flow Electroporation technology designed to efficiently and safely modify human cells with high efficiency, low cytotoxicity, and scalability for clinical use.
| Founded: | 1999 | Country: | United States |
| Employees: | N/A | City: | ROCKVILLE |
| Market Cap: | 136.2M | IPO Year: | 2021 |
| Target Price: | $5.50 | AVG Volume (30 days): | 881.8K |
| Analyst Decision: | Buy | Number of Analysts: | 4 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.13 | EPS Growth: | -7.69 |
| 52 Week Low/High: | $0.64 - $1.86 | Next Earning Date: | 05-12-2026 |
| Revenue: | $33,026,000 | Revenue Growth: | -14.50% |
| Revenue Growth (this year): | -1.87% | Revenue Growth (next year): | 18.50% |
| P/E Ratio: | -10.62 | Index: | N/A |
| Free Cash Flow: | -36178000.0 | FCF Growth: | N/A |
AI-Powered MXCT Daily Prediction
Machine learning model trained on 25+ technical indicators
AI Recommendation
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Earnings Transcripts
SEC 8-K filings with transcript text
2026 Q2 Q2 2026 Earnings
8-K SELL Aug 12, 2026 · 100% conf.
Q2 2026 Earnings
8-K SELLAug 12, 2026 · 100% conf.
1D
-8.24%
$1.17
Act: +9.47%
5D
-10.36%
$1.14
20D
-9.07%
$1.15
EX-99.1
2 mxct-20260812xex99d1.htm
EX-99.1
Exhibit 99.1
MaxCyte Reports Second Quarter 2026 Financial Results
·
Reports total revenue of $7.3 million for the second quarter of 2026, including $6.5 million of core revenue and $0.8 million of SPL Program-related revenue
·
Reiterates Full Year 2026 Guidance
·
Repurchased approximately $5.5 million of common stock to date under the Company’s $10 million share repurchase program authorized by the Board
·
Following end of quarter, announced strategic, multi-platform technology license partnership with Genentech in July
ROCKVILLE, MD, August 12, 2026 — MaxCyte, Inc. (NASDAQ: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics, today announced its second quarter ended June 30, 2026 financial results and reiterated its 2026 guidance.
"We are pleased with our second quarter results, which were ahead of our expectations, driven by execution on instrument placements and stability in processing assembly sales," said Maher Masoud, President and CEO of MaxCyte. "A significant development for MaxCyte was the recent signing of our first multi-platform technology license partnership with large pharma, an enterprise-level agreement with Genentech that we believe will unlock meaningful new opportunities for MaxCyte. Separately, our SPL portfolio remains a key driver of long-term value as evident by growing commercial royalty revenue and the advancement of a significant number of SPL programs through the clinic. Lastly, our goal has been to return to revenue growth while reducing our net losses. In the first half of 2026, we delivered a meaningful reduction in net loss and expect to benefit further as we continue to execute against our plan and return to revenue growth.”
Second Quarter Financial Results
·
Total revenue of $7.3 million in the second quarter of 2026, a decrease of 15% over the second quarter of 2025.
o
Core business revenue of $6.5 million in the second quarter of 2026, a decrease of 21% over the second quarter of 2025.
o
Strategic Platform License (SPL) Program-related revenue was $0.8 million for the second quarter of 2026, compared to $0.3 million in the second quarter of 2025.
·
Gross profit for the second quarter of 2026 was $5.6 million (77% gross margin), compared to $7.0 million (82% gross margin) in the second quarter of 2025.
·
Non-GAAP adjusted gross margin was 77% when excluding SPL Program-related revenue and reserves for excess and obsolete inventory, compared to non-GAAP adjusted gross margin of 83% in the second quarter of 2025.
·
Operating expenses for the second quarter of 2026 were $15.8 million, compared to operating expenses of $21.2 million in the second quarter of 2025.
·
Second quarter 2026 net loss was $8.9 million compared to net loss of $12.4 million for the same period in 2025.
1
·
EBITDA, a non-GAAP measure, was a loss of $9.3 million for the second quarter of 2026, compared to a loss of $13.1 million for the second quarter of 2025; stock-based compensation expense was $1.2 million in the second quarter of 2026 compared to $3.5 million in the second quarter of 2025.
·
Total SPL agreements was 29 as of June 30, 2026, which includes 12 programs currently in the clinic (defined as programs with at least a cleared IND or equivalent) and one commercial program.
·
Total cash, cash equivalents and investments were $141.9 million as of June 30, 2026.
Full Year 2026 Guidance
·
Full year revenue expected to be $30 million to $32 million consisting of:
o
Core revenue of $25 million to $27 million.
o
SPL Program-related revenue of approximately $5 million for the year; SPL Program-related revenue guidance includes both revenue of approximately $3 million from milestone payments and approximately $2 million from commercial royalties.
·
MaxCyte expects to end 2026 with at least $130.5 million in total cash, cash equivalents and investments, excluding any further capital deployed toward the share repurchase program.
The following tables provide details regarding the sources of our revenue for the periods presented.
Three Months Ended
June 30 (Unaudited)
2026
2025
%
(in thousands, except percentages)
Instruments
$
1,761
$
2,141
(18%)
PAs and Consumables
2,337
3,128
(25%)
Licenses
1,822
2,619
(30%)
Assay Service
245
51
380%
Other
338
259
31%
Total Core Revenue
$
6,503
$
8,198
(21%)
Milestones
4
4
0%
Royalties
764
305
150%
Total Revenue
$
7,271
$
8,507
(15%)
Webcast and Conference Call Details
MaxCyte will host a conference call today, August 12, 2026, at 4:30 p.m. Eastern Time. Investors interested in li
2026 Q1 Q1 2026 Earnings
8-K BUY May 12, 2026 · 100% conf.
Q1 2026 Earnings
8-K BUYMay 12, 2026 · 100% conf.
1D
+3.60%
$0.85
Act: +24.06%
5D
+9.63%
$0.90
Act: +26.49%
20D
+8.22%
$0.89
Act: +39.87%
EX-99.1
2 mxct-20260512xex99d1.htm
EX-99.1
Exhibit 99.1
MaxCyte Reports First Quarter 2026 Financial Results and Reiterates Full Year 2026 Guidance
First quarter 2026 total revenue of $9.7 million, including $6.2 million of core revenue and $3.4 million of SPL Program-related revenue
Reiterates 2026 revenue guidance of $30-32 million; with Core revenue of $25-27 million and Strategic Platform License (SPL) Program-related of $5 million
MaxCyte’s Board authorized a $10 million share repurchase program
ROCKVILLE, MD, May 12, 2026 — MaxCyte, Inc., (NASDAQ: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics, today announced its first quarter ended March 31, 2026 financial results and reiterated its 2026 guidance.
“We are pleased with our performance in the first quarter, and remain confident in our full year guidance,” said Maher Masoud, President and CEO of MaxCyte. “Our core revenue from partners and customers was in line with our expectations for both our ExPERT electroporation platforms and SeQure services. The SPL portfolio continues to advance in the clinic, including a clinical customer that began dosing patients in a registrational study in the first quarter, and we remain confident additional customers will initiate registrational trials this year. Further, our SPL portfolio remains strong and spans a broad range of modalities and indications. MaxCyte remains extremely well positioned in the cell & gene therapy industry, with leading technology and an efficient cost structure. Reflecting continued confidence in our strategy and the long-term value of our business, the Board today authorized a $10 million share repurchase. This authorization provides us with flexibility in capital allocation while we continue to invest in key growth initiatives, including the recent launch of ExPERT DTx and the integration of SeQure Dx. We believe this balanced approach enables us to both reinvest in the business and return capital to shareholders.”
First Quarter Financial Results
·
Total revenue of $9.7 million in the first quarter of 2026, a decrease of 7% over the first quarter of 2025.
o
Core business revenue of $6.2 million in the first quarter of 2026, a decrease of 25% over the first quarter of 2025.
o
Strategic Platform License (SPL) Program-related revenue was $3.4 million for the first
o
quarter of 2026, compared to $2.1 million in the first quarter of 2025.
·
Gross profit for the first quarter of 2026 was $8.1 million (84% gross margin), compared to $8.9 million (86% gross margin) in the first quarter of 2025.
·
Non-GAAP adjusted gross margin was 78% when excluding SPL Program-related revenue and reserves for excess and obsolete inventory, compared to non-GAAP adjusted gross margin of 83% in the first quarter of 2025.
·
Operating expenses for the first quarter of 2026 were $14.3 million, compared to operating expenses of $21.2 million in the first quarter of 2025.
1
·
First quarter 2026 net loss was $4.8 million compared to net loss of $10.3 million for the same period in 2025.
·
EBITDA, a non-GAAP measure, was a loss of $5.1 million for the first quarter of 2026, compared to a loss of $11.2 million for the first quarter of 2025; stock-based compensation expense was $1.1 million in the first quarter of 2026 compared to $3.0 million in the first quarter of 2025.
·
Total SPL agreements was 29 as of March 31, 2026, which includes 12 programs currently in the clinic (defined as programs with at least a cleared IND or equivalent) and one commercial program.
·
Total cash, cash equivalents and investments were $147.7 million as of March 31, 2026.
Full Year 2026 Guidance
·
Full year revenue expected to be $30 million to $32 million consisting of:
o
Core revenue of $25 million to $27 million.
o
SPL Program-related revenue of approximately $5 million for the year; SPL Program-related revenue guidance includes both revenue of approximately $3 million from milestone payments and approximately $2 million from commercial royalties.
·
MaxCyte expects to end 2026 with at least $136 million in total cash, cash equivalents and investments, which does not include capital to be used for the share repurchase program.
The following tables provide details regarding the sources of our revenue for the periods presented.
Three Months Ended
March 31
(Unaudited)
2026
2025
%
(in thousands, except percentages)
Instruments
$
1,346
$
1,444
(7%)
PAs and consumables
2,293
3,871
(41%)
Licenses
2,097
2,531
(17%)
Assay service
188
142
32
%
Other
294
255
15
%
Total Core Revenue
$
6,218
$
8,243
(25%
2025 Q4 Q4 2025 Earnings
8-K SELL Mar 24, 2026 · 100% conf.
Q4 2025 Earnings
8-K SELLMar 24, 2026 · 100% conf.
1D
-8.78%
$1.24
Act: -3.68%
5D
-10.78%
$1.21
Act: -11.03%
20D
-8.62%
$1.24
Act: -43.38%
EX-99.1
2 mxct-20260324xex99d1.htm
EX-99.1
Exhibit 99.1
MaxCyte Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Full Year 2026 Guidance
Fourth quarter 2025 total revenue of $7.3 million at the top of the range of previous preliminary announcement
Full year 2025 revenue of $33.0 million, at the top of the range of previous preliminary announcement
Total cash, cash equivalents and investments were $155.6 million as of December 31, 2025. Expects to end 2026 with at least $136 million in total cash, cash equivalents and investments
Expects 2026 revenue of $30-32 million; with Core revenue of $25-27 million and Strategic Platform License (SPL) Program-related of $5 million
ROCKVILLE, MD, March 24, 2026 — MaxCyte, Inc., (NASDAQ: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics, today announced its fourth quarter and full year ended December 31, 2025 financial results and initiated its 2026 guidance.
“Our 2025 revenues were impacted by headwinds from select SPL customers, including a 15% reduction in purchases and leases from our largest customer, which we expect to stabilize in the second half of 2026 and grow from that new base. Despite these near-term challenges, we made meaningful progress in 2025: reducing annual cash burn by more than $16 million, streamlining our cost structure, and advancing new product launches, all which we believe will strengthen MaxCyte's position in the growing cell and gene therapy market for the long term,” said Maher Masoud, President and CEO of MaxCyte.
“We also continued to expand our SPL portfolio, by signing 4 new SPLs in 2025. As we look ahead to 2026, we will focus on growing our sales pipeline across our ExPERT electroporation platform and SeQure assay services business units, including driving growth in our new ExPERT DTx discovery platform which launched last month. Our 2026 total revenue guidance calls for $30-32 million, which we believe is appropriate as it includes approximately $4 million in core revenue headwind from select SPL customers, which began to impact revenue in the second half of 2025. I remain more excited than ever in the future growth of our company. I believe we now will be supporting up to four therapies in Phase III by the end of 2026 and have already received a milestone payment for one of these therapies. The expansion of CGT, including ongoing clinical progress, which we are part of, underpins the long-term opportunity for MaxCyte,” he added
Fourth Quarter and Full Year Highlights
●Total revenue of $7.3 million in the fourth quarter of 2025, a decrease of 16% over the fourth quarter of 2024.
oCore business revenue of $6.8 million in the fourth quarter of 2025, a decrease of 22% over the fourth quarter of 2024.
1
oStrategic Platform License (SPL) Program-related revenue was $0.5 million for the fourth quarter of 2025, compared to $0.1 million in the fourth quarter of 2024.
●Total revenue of $33.0 million for the full year 2025, a decrease of 15% over the full year 2024.
oCore business revenue of $29.6 million for the full year 2025, a decrease of 9% over the full year 2024.
oSPL Program-related revenue was $3.4 million for the full year 2025, compared to $6.1 million in full year 2024.
●Ended the year with 32 SPL agreements that include 13 programs currently in the clinic (defined as programs with at least a cleared IND or equivalent) and one commercial program.
●Total cash, cash equivalents and investments were $155.6 million as of December 31, 2025.
The following tables provide details regarding the sources of our revenue for the periods presented.
Three Months Ended
Year Ended
December 31,
December 31,
2025
2024
%
2025
2024
%
(Unaudited)
(Unaudited)
(in thousands, except percentages)
Instrument
$
1,841
$
1,629
13
%
$
6,802
$
7,083
(4%)
PAs and consumables
2,312
4,169
(45%)
11,889
14,006
(15%)
Licenses
1,993
2,554
(22%)
8,946
10,297
(13%)
Assay Services
335
—
—
776
—
—
Other
274
258
6
%
1,190
1,126
6
%
Total Core Revenue
$
6,755
$
8,610
(22%)
$
29,603
$
32,512
(9%)
Milestones
4
4
0
%
2,265
6,015
(62%)
Royalties
541
79
586
%
1,158
100
(44%)
Total Revenue
$
7,300
$
8,693
(16%)
$
33,026
$
38,627
(15%)
In addition to revenue, management regularly reviews key business metrics to evaluate our business, measure
Compare MXCT vs Leading Stocks
See how MXCT stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "MXCT MaxCyte Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.